AMARIN CORP PLCUKAMRNEarnings & Financial Report

Nasdaq · pharmaceutical industry

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

NextMar 31, 2026

Revenue

$49.7M

Gross Profit

$22.2M

Operating Profit

$-11.1M

Net Profit

$-7.7M

Gross Margin

44.7%

Operating Margin

-22.4%

Net Margin

-15.6%

YoY Growth

17.4%

EPS

$-0.02

Financial Flow

AMARIN CORP PLCUK Q3 2025 Financial Summary

AMARIN CORP PLCUK reported revenue of $49.7M for Q3 2025, with a net profit of $-7.7M (-15.6% margin). Cost of goods sold was $27.5M, operating expenses totaled $33.3M.

Key Financial Metrics

Total Revenue	$49.7M
Net Profit	$-7.7M
Gross Margin	44.7%
Operating Margin	-22.4%
Report Period	Q3 2025

AMARIN CORP PLCUK Annual Revenue by Year

AMARIN CORP PLCUK annual revenue history includes year-by-year totals (for example, 2024 revenue was $228.6M).

Year	Annual Revenue
2024	$228.6M
2023	$306.9M
2022	$369.2M

Income Statement

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Revenue	$74.7M	$56.5M	$67.5M	$42.3M	$62.3M	$42.0M	$72.7M	$49.7M
YoY Growth	-17.2%	-34.3%	-15.8%	-36.0%	-16.6%	-25.7%	7.8%	17.4%

Balance Sheet

	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025
Assets	$831.7M	$790.0M	$799.9M	$750.6M	$685.3M	$655.7M	$670.1M	$659.8M
Liabilities	$279.6M	$244.1M	$248.0M	$219.2M	$199.2M	$182.0M	$205.2M	$200.9M
Equity	$552.1M	$545.9M	$551.9M	$531.4M	$486.2M	$473.7M	$464.9M	$458.9M